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Introduction
An increasing number of patients require dialysis
replacement therapy every year in Europe. This
reflects the large number of patients with chronic
renal failure (CRF) and the progressive nature of their
underlying nephropathies. Worldwide, the annual
incidence of acceptance rates on renal replacement
programmes varies between 25 patient per million of
population (pmp) in some developing countries to
58.6 pmp in Europe, 169 pmp in the USA [I] and
194.2 pmp in Japan [2]. In Europe, there are in excess
of 312 pmp on replacement therapy with France
having one of the highest prevalence within the
continent with 628 pmp [3]. Further, there are
important differences in the incidence of end stage
renal failure (ESRF) according to age, gender and
race. In Western countries, the incidence of ESRF is
lowest in children (10 pmp/year) and highest in the
elderly (> 400 pmp/year in patients over the age of
75). The incidence of ESRF is higher in males. In the
United States, the incidence of ESRF is higher in
Afro-Carribeans and native Americans [4]. This
reflects both an increased prevalence of CRF in these
ethnic minorities as well as a higher rate of
progression [4]. It also reflects the higher incidence
of systemic hypertension and diabetic nephropathy in
black and native Americans respectively [4]. In the
United Kingdom, the incidence of ESRF is higher in
Asians [5].
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Pathophysiology of progressive eRF
The progression of CRF is associated histologically
with progressive glomerulosclerosis, tubulointerstitial
fibrosis and vascular sclerosis. Research undertaken
over the last quarter of a century has improved our
understanding of the pathophysiology of these
histological changes.
Glomerulosclerosis is associated with progressive
renal scarring regardless of the nature of the initiating
nephropathy. Numerous hypotheses have been put
forward to explain the progressive nature of
glomerulosclerosis. These have included the
suggestion that the adaptive haemodynamic or
morphological glomerular changes observed in
remnant glomeruli after the loss of functional renal
mass initiate glomerulosclerosis. The compensatory
glomerular hyperperfusion, hyperfiltration or hyper-
tension (a rise in intraglomerular capillary pressure)
[6] or the associated glomerular hypertrophy [7] have
all been implicated as maladaptive in the longterm
contributing to the progression of glomerulosclerosis.
The hyperperfusion / hyperfiltration hypothesis
stipulated that a low protein diet would be protective
against glomerulosclerosis through the correction of
the adaptive haemodynamic changes [6]. Conversely,
a high protein diet on the other hand has been shown
to be detrimental to the progression of experimental
glomerulosclerosis [8].
Others have implicated the nephrotoxicity of lipids
rather than protein linking the rise of circulating
lipids in CRF with their deposition within scarred
glomeruli and their acceleration of the glomerular
scarring process [9]. Since, a large body of evidence
has confirmed that low density lipoproteins, in
particular when oxidized, are nephrotoxic to
glomerular cells [10]. A role for lipids in the
pathogenesis of glomerulosclerosis has also drawn
attention to the similarities between this process and
that of atherosclerosis [11]. These similarities involve
endothelial injury, platelet aggregation, the infiltr-
ation of the vascular/glomerular wall by monocytes/
macrophages and the proliferation of smooth muscle/
mesangial cells. Interactions between infiltrating and
resident glomerular cells are mediated by the release
of cytokines, chemokines and growth factors [12].
These mediators contribute to the proliferation of
mesangial cells and their stimulation for the synthesis
of components of extracellular matrix (ECM). These
mitogenic and fibrogenic factors include growth
factors such as platelet derived growth factor (PDGF)
and transforming growth tactor-B (TGF-~), cytokines
such as interleukins I and 6 (IL-I and 6) and tumour
necrosis factor-a (TNF-a) and chernokines such as
monocyte chemoattractant protein-I (MCP-I) and
macrophage inflammatory protein-2 (MIP-2) [13]. Of
these TGF-~ is thought to be the most fibrogenic
[14]. The accumulation of ECM within scarred
glomeruli and their inability to break it down
culminates in fibrosis and the obsolescence of the
glomeruli.
The pathogenesis of tubulointerstitial fibrosis (TIF)
has also received renewed interest recently. This is
more relevant since the severity of tubulointerstitial
fibrosis correlates better with the degree of chronic
renal insufficiency when compared to glomerulo-
sclerosis [15]. As with glomerulosclerosis, HF has
been the subject of numerous speculations and
hypotheses. These included the adaptive hyper-
function of remnant proximal tubules in response to
renal functional loss, the nephrotoxicity of lipids, that
of iron and oxygen free radicals [16]. More recently,
some have suggested that proteinuria itself was
nephrotoxic [17]. This is supported by experimental
observations showing that the exposure of proximal
tubular cells in culture lO albumin, transferrin or
serum leads to their release of cytokines, growth
factors and chemotactic peptides such as osteopontin
[18]. Further, tubular cells respond to proteins by
switching on their synthesis of ECM [18]. The
release by tubular cells of chemotactic and mitogenic
factors contribute to the attraction of, and infiltration
of scarred kidneys by, lympho-monocytic cells. Such
infiltrate is likely to play a central role in the
progression of TIF. Inflammatory cells would i.n turn
activate and stimulate the proliferation of interstitial
and perivascular renal fibroblasts. The activation of
these cells leads to their acquisition of myofibro-
blastic phenotypes and the expression of cytoskeletal
proteins such as a-smooth muscle actin (a-SMA)
[19]. Myofibroblasts progressively invade the scarred
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renal interstitium and contribute to the progression of
interstitial fibrosis [19].
Vascular sclerosis often features along with
glomerulosclerosis and TJF in scarred kidneys.
Whislt it is likely to reflect the superimposed
systemic hypertension, the severity of arteriolar
hyalinosis / sclerosis is not uncommonly' out of
proportion to the sevrity of hypertension. Such
vascular sclerosis may contribute to the progression
of renal scarring through its ischemic effect on the
remaining renal parenchyma thus exacerbating
glomerulosclerosis and TIF and generating a vicious
cycle culminating in end stage renal insufficiency
[20]. Further, vascular injury may lead to the
activation of adventitial, perivascular, myofibroblasts
and their migration into the renal interstitium as
described above.
Management of experimental progressive renal
failure
The advances and insights made in our understanding
of the mechanisms of progressive renal scarring have
suggested a broad range of dietary and pharma-
cological approaches. In experimental animals,
dietary protein restriction attenuates the development
of glomerulosclerosis and slows the progression of
CRF [8]. Other dietary interventions which proved to
be protective have included dietary restrictions of
phosphate, salt, sucrose, calories and saturated fats
[8]. On the other hand, the supplementation of diet
with polyunsaturated fatty acids, including fish oil
(eicosapentaenoic acid) and an increase water intake
are also protective against the progression of
experimental renal insufficiency [8].
Numerous pharmacological interventions have also
been tested with some success in experimental
animals with progressive renal fai lure [21]. These
have included the administration of antiplatelets
agents and anticoagulants [21]. The reduction of renal
monocytic infiltration by diets or drugs have also
prevented the progression of experimental renal
scarring [8, 21]. Inhibition of cytokines, chemokines
and growth factors with neutralizing antibodies or
receptor antagonists have been effective in
attenuating the severity of glomerulosclerosis and
proteinuria and preserving renal function in rats with
progressive renal diseases [II]. Finally, the reduction
of systemic hypertension reduces proteinuria and
preserves renal function in experimental models of
renal scarring [21]. Some have suggested that all
antihypertensive agents were not equally protective
with angiotensin converting enzyme inhibitors being
the most effective [21]. Others have shed some doubt
on such assumptions and argued that the protective.
effect of antihypertensive agents in rats depends on
the quality of systemic blood pressure control
3regardless of the nature of the antihypertensive agent
used [22].
Clinical interventions in CRF
As in experimental animals a wide range of
interventions have been applied to slow the
progression of clinical nephropathies. These have
included dietary and pharmacological interventions.
Dietary interventions have included dietary protein
and or phosphate restrictions as well as the
supplementation of diets with fish oil. Dietary protein
restrictions have been recommended to patients with
progressive CRF for the last 30 years [23].
Numerous studies have suggested that such
interventions slowed the progression of renal
diseases. However, upon close scrutiny it became
evident that many such clinical trial were flawed with
inappropriate controls, small numbers of patients,
limited follow-up time as well as the reliance on the
use of serum creatinine measurements to estimate the
rate of the progression of CRF [24]. The latter is now
known to be an unreliable marker of progression
when dietary protein intake is reduced leading to
changes in the intake of creatine, its metabolism,
generation and excretion [25]. Further, very few of
the initial uncontrolled studies on dietary protein
restriction payed attention to the impact of such an
intervention on the nutritional status of patients with
progressive renal insufficiency [24]. Over the last ten
years, efforts have been made to conduct larger and
better controlled prospective clinical trials on the
effect of low protein diets (LPD) on the progression
of CRF. Unfortunately, these have remained
inconclusive. Some were inconclusive because of the
poor compliance of patients to the dietary protein
restriction [26]. Others had too small a number of
patients making the statistical interpretation doubtful
[27]. The largest study conducted so far is the
Modification of Diet in Renal Disease (MRD)
performed in the USA [28]. This study looked at 585
patients with a GFR between 25 and 55 ml/min and
255 patients with values between 13 and 24 ml/min.
Both groups were randomly allocated a target mean
arterial blood pressure of 92 to 107 mmhg. The first
group was randornised into a protein intake of 1.3
g/kg/day or 0.6g/kg/day. The second group received
0.6g/kg/day or 0,3g/kg/day supplemented with a
keto-amino acid mixture. Patients were followed up
for up to 36 months (average 2.2 years). The
projected mean declines in GFR over 3 years was not.,
different between the experimental groups. Of
interest, patients on a L..PDhad a faster decline in the
renal function (reciprocal of serum creatinine) over
the first 4 months of the study, thereafter they may
have had a slower rate of progression. Recently, the
results of the MRD were reanalysed and suggestions
were made that a reduction in actual protein intake of
0.2 g/kg/day was associated with a 29% lower rate of
decline in GFR in patients with an initial value of less
than 25 ml/min [29]. A metaanalysis of all major
trials on LPD has also suggested a relative risk for
ESRF on LPD of 0.67 (95% Cl, 0.5 to 0.89) [30].
However, in this meta analysis included various trials
with different levels of dietary protein reduction and
consumption, different ways of measuring prog-
ression and different end points [30]. This hetero-
geneity makes, in my mind, such analysis pointless.
Before advocating dietary protein reduction, it is
important to remember that it is often associated with
wasting and malnutrition. Even the MRD patients lost
weight [28]. As malnutrition is a major adverse risk
factor on dialysis, it is therefore unreasonalble to
compromise the nutritional well being of CRF
patients with a LPD for a doubtful, or marginal at
best, effect on the rate of progression of their disease.
Finally, what is the point of prescribing LPDs when it
has been clearly shown that patients with ESRF
reduce spontaneously their protein intake to around O.
6g/kg/day , ? [31].
Other dietary interventions have focused on dietary
restriction of phosphate. The only randomised study
addressing this issue failed to show a difference in
the progression rate of CRF on such a diet [32].
Studies of dietary supplementation with fish oil in
CRF have shown conflicting results. The study
showing a beneficial effect on the progression of
mesangial IgA nephropathy in the USA was tlawed
by the unusually fast rate of progression of their
control group [33]. The rate of progression of patients
on fish oil (eicosapentaenoic acid supplementation)
was in fact comparable to published reports of
untreated patients with IgA nephropathy in Europe.
With respect to pharmacological interventions, most
have proved of little efficacy in patients with CRF.
Antiplatelet agents and anticoagulants failed to affect
the natural history of chronic glomerulonephritis
[23]. Immunosuppression is difficult to evaluate in
view of the heterogenous nature of primary and
secondary glomerulonephritides. However, some
trials warrant Comments if only to highlight the
difficulties with longterm studies of interventions in
progressive CRF. In membranous nephropathy, an
Italian group has repeatedly shown that a combin-
ation of chlorambucil and steroids slowed the
progression of the disease [34]. When a long term
study of the natural history of the disease was
compared to the results of these intervention trials it
appeared that the progression rate of patients with
membranous nephropathy treated with chlorambucil
and' steroids was comparable to untreated patients
[35]. Furthermore, immunosuppresion was not
without its associated morbidity and mortality [34].
Studies from the NTH in the USA on the effect of
immunosuppression on the progression of CRF in
patients with lupus nephropathies have suggested that
combination immunosuppression with steroids and
cyclophosphamide may be advantageous [36].
Careful analysis of these studies highlights their
uncontrolled nature as comparisons were made
between current interventions and those practised in
the sixties and seventies ! [36]. Furthermore,
statistical significance was only noted when the
number of patients followed-up had fallen drastically,
thus casting doubt on the significance of the
di fferences between the groups based on actuarial
survival analysis [36]. In conclusion, we need, as
practitioners, to be vigilant in our interpretation of
published data. Sometimes, close scrutiny of the
literature may avoid unproven, unnecessary and
potentially harmful interventions.
It is safe to say that the only intervention of proven
benefit in patients with CRF is the control of
systemic blood pressure. While even this intervention
has not been the subject of rigorous, prospective and
randomised testing, it is safe to say that retrospective
and prospective analysis have suggested a slowing
down of the rate of decline in CRF of patients whose
blood pressure is well controlled. Two questions
follow; the first, what is the optimal level of blood
pressure control we should aim for? and the second,
which antihypertensive agent should we use?
In answer to the question of level of blood pressure
control, some have suggested that patients with a
diastolic blood pressure inferior to 90 mmhg had a
rate of decline of GFR 50% slower than those with
higher values [37J. No additional benefit seemed to
be gained from a reduction of diastolic blood pressure
to values lower than 85-90 mmhg [37). This was
confirmed by a prospective, albeit small study [38].
Others have suggested that the improvement in renal
function is proportional to the degree of reduction in
mean arterial pressure [39). However, in this study
most patients achieved mean arterial pressure levels
between 100 and 102 mmHg and not lower.
Interesting observations were recently derived from
the MRD study relating to the optimal level of blood
pressure control. It was suggested that patients with
proteinuria benefit from a lower blood pressure when
compared to the others [40). Individuals with more
than I g/day of proteinuria needed a mean arterial
blood pressure around 92 mmhg (125/75 mmhg) to
acheive a similar reduction in the rate of decline in
GFR to those with less proteinuria and a mean
arterial pressure of 98 mmhg (130/80 mmhg) [40].
Thus, the target of blood pressure control may need
to take into consideration the severity of proteinuria
with lower targets set for patients with heavy
proteinuria.
The next question which arises is which drug should
we use to treat hypertension in CRF. Some studies
suggested that angiotensin converting enzyme (ACE)
inhibitors were more protective when compared to
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conventional agents (diuretics, beta-blockers and
calcium antagonists). Two large prospective studies
one in diabetic patients [41] and the other in non-
diabetic patients [42] with progressive CRF reported
a beneficial effect of ACE inhibitors. Both these
studies have their limitations as they both showed a
better blood pressure control in patients treated with
the ACE inhibitor compared to those on the other
agents, thus not excluding the possibility that the
additional benefit derived from a better overall blood
pressure control regardless of the agent used.
Furthermore, the way blood pressure was measured
in these studies, casually and at long intervals, does
not give the investigators an overall picture of the
quality of blood pressure control. More frequent and
more prolonged (24 hour) blood pressure monitoring
is needed to ascertain whether ACE inhibitors
provide additional advantages independently of blood
pressure control. Meta-analysis has shown that ACE
inhibitors are indeed more effective in reducing
proteinuria in diabetic and nondiabetic nephropathies
when compared to other antihypertensive agents [43].
Other prospective studies failed to show a beneficial
effect of ACE inhibitors when compared to calcium
antagonists [44,45]. Furthermore, in patients with
polycystic kidney disease [46] as well as in the
elderly [47), ACE inhibitors appear to accelerate the
rate of decline in renal function. These agents are not
without their potential nephrotoxicity in patients with
a reduction in residual renal function. It is imperative
to be selective and cautious in prescribing them as
they can lead to an acceleration in the decline in renal
function which can, on occasions, be irreversible
[48]. Finally, the therapeutic potential .of ACE
inhibitors may be affected by the patients' genotype
as in one study patients with the ACE genotype (II)
had the best response to treatment with ACE
inhibitors while those with the genotype (DO)
responded poorly [49].
Clinical recommendations
In patients with progressive CRF our main aim
should be to avoid harm. This entails avoidance of
nephrotoxic investigations (radiocontrast material)
and drugs (non steroidal anti-inflammatory agents
and ACE inhibitors). We should also be vigilant as to
the causes of acute on chronic deteriorations in renal
function, such as obstruction (prostatic hypertrophy
amongst others) or renovascular disease in the
elderly. Both should be addressed and corrected to
prevent ESRF. We should follow up patients
frequently and closely. We should avoid excessive
protein intake but not impose dietary restrictions that
could compromise their nutritional status or the
quality of their lives. We should correct the metabolic
consequences of CRF including hypocalcaemia,
5hyperphosphatemia and not forget the correction of
metabolic acidosis as it contributes to renal osteo-
dystrophy and malnutrition. We should detect,
monitor and treat hypertension to the best of our
abilities. Finally, we should attempt to initiate
dialysis replacement therapy at an optimal time
before the onset of significant malnutrition or
cardiovascular complications as both will ultimately
determine the outcome of these patients. This often
means avoiding undue delay in the initiation of
dialysis in the misplaced hope that some intervention
is preserving renal function.
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